A middle-aged female patient presented to us with "recurrence of a right retroperitoneal tumor after resection 10 months after the second operation". In November 2016, the patient underwent retroperitoneal dedifferentiated liposarcoma resection. The second recurrence surgery was performed in October 2017. In January 2018, CT showed no recurrence, and no metastasis was found in the hepatic and gastric space nodules. In August 2018, Professor Lin Lizhu visited the outpatient clinic. She had four diagnoses: fatigue, obvious right flank migratory pain, sometimes needle-like pain, sometimes dull pain, occasionally dry mouth, phlegm in the pharynx, nausea and vomiting, poor sleep, and second constipation. Tongue pale moss white greasy, pulse slippery. Treatment: invigorating spleen and removing phlegm, soft and firm dispersing knots, adding or subtracting self-designed removing phlegm and dispersing knots for 2 years, combined with anlotinib for 19 months, the recurrence of right middle and lower retroperitoneal tumor slowly increased. In September 2020, "retroperitoneal tumor resection + right kidney resection + right adrenal resection + right hemicolectomy + diaphragmatic repair" was performed, and postoperative traditional Chinese medicine treatment was performed. The patient was treated with pure traditional Chinese medicine after three recurrence operations, and the disease-free survival time was 22 months. By July 2022, the patient was still followed up, and the OS was as long as 5 years and 8 months,TCM diagnosis,　TCM diagnosis of sarcoma phlegm wet condensation syndrome;,Western medicine diagnosis,　postoperative recurrence of right retroperitoneal dedifferentiated liposarcoma stage IV.,Therapeutic methods,　The patients were treated with self-designed Jietan Sanjie prescription combined with anlotinib after the operation. The patients were treated with pure traditional Chinese medicine after surgical resection after three recurrence.,Clinical outcomes,　The patient relapsed 9 months after the first operation and 10 months after the second operation. After targeted therapy with traditional Chinese medicine combined with anlotinib, the patient achieved 19 months of tumor-carrying survival, and 22 months of disease-free survival after the third operation. No recurrence or metastasis was found in the current follow-up, and the overall survival has reached 5 years and 8 months, far longer than 8-13 months reported in the literature.